Abstract
Hypopigmented disorders in childhood encompass a broad spectrum of presentations, including depigmentation, hypopigmentation, and pseudo-hypopigmentation arising from non-melanin mechanisms. In clinical practice, the primary challenge often lies in distinguishing these conditions from vitiligo, the most common acquired depigmentation disorder. Although vitiligo is categorized into nonsegmental and segmental subtypes, many children initially present with an undetermined or focal form before the clinical subtype is clearly established. A systematic diagnostic approach begins with Wood’s lamp examination and ultraviolet photography to distinguish complete depigmentation from partial hypopigmentation, followed by assessment of onset, extent, distribution, and associated extracutaneous manifestations. Accurate diagnosis enables early therapeutic intervention for vitiligo, averts unnecessary anxiety regarding self-limiting conditions, and prompts appropriate systemic evaluation. This review provides a comprehensive, evidence-based clinical framework for the differential diagnosis of pediatric hypopigmented disorders, highlighting key diagnostic clues to facilitate accurate diagnosis and optimal management.
Keywords: Children, Differential diagnosis, Hypopigmentation, Vitiligo
INTRODUCTION
Hypopigmented skin lesions constitute one of the most frequently encountered dermatologic conditions in children1, which often cause profound distress for caregivers, specifically regarding the potential diagnosis of vitiligo2. Although vitiligo remains the most common cause of acquired depigmentation in childhood3, a considerable proportion of children presenting with pigment loss are ultimately diagnosed with mimicking conditions. The differential diagnosis is broad, encompassing transient, self-limiting entities and cutaneous manifestations of genodermatoses and systemic syndromes1,4. Differentiating vitiligo from its mimics poses a significant clinical challenge, particularly when clinical features are subtle or atypical. Accurate diagnosis carries substantial prognostic and therapeutic implications: it averts unnecessary anxiety regarding benign, self-resolving conditions while facilitating timely recognition of disorders necessitating early intervention or systemic evaluation.
This review provides a systematic diagnostic framework that utilizes specialized imaging modalities to characterize lesion features, sequentially analyzes onset, distribution, and extent, and offers a comprehensive, evidence-based overview of vitiligo and other hypopigmented disorders in children.
DIAGNOSTIC MODALITIES FOR HYPOPIGMENTED DISORDERS
The first step in diagnosing pediatric hypopigmented disorders is a thorough clinical examination, supplemented by specialized imaging modalities. A multimodal approach utilizing cross-polarized light, Wood’s lamp, ultraviolet (UV) photography, and dermoscopy is instrumental in characterizing lesion shape, color, border, and extent (Fig. 1).
Fig. 1. Diagnostic modalities for hypopigmented disorders in children. (A) Natural light has limited sensitivity, particularly in fair-skinned children, owing to low melanin contrast and surface glare. (B) Cross-polarized light eliminates surface glare, enhancing subsurface pigment visualization. (C) Wood’s lamp examination accentuates the distinction between complete depigmentation and partial hypopigmentation. (D) Ultraviolet photography provides the highest sensitivity for subtle pigmentary changes and objective documentation for monitoring disease progression.

Cross-polarized imaging tools employ two perpendicular filters to eliminate surface reflections, and enable visualization of deeper skin structures such as vasculature and pigment5. Wood’s lamp, which emits UV light at a peak wavelength of 365 nm, is indispensable in the examination of hypopigmented lesions. Melanin absorbs UV light; thus, complete melanin loss (depigmentation) results in enhanced fluorescence of the underlying dermal collagen, producing a bright blue-white appearance, whereas partial pigment loss (hypopigmentation) appears as a dull off-white without such enhancement6. This distinction is diagnostically critical: vitiligo exhibits characteristic “chalky-white” fluorescence, whereas hypopigmented conditions do not7. UV photography offers greater sensitivity and reproducibility compared to bedside Wood’s lamp examination alone. It enhances visibility by maximizing contrast and provides objective documentation for monitoring disease progression and evaluating treatment response8. UV photography complements rather than replaces Wood’s lamp examination since subtle hypopigmented lesions and early vitiligo may appear similar on UV photographs; accurate grading of pigment loss thus remains challenging.
Skin biopsy is rarely required but is essential to confirm certain diagnoses. Non-invasive alternatives, such as dermoscopy and reflectance confocal microscopy (RCM) may serve as adjunctive tools. Dermoscopic examination can help distinguish vitiligo from nevus depigmentosus by revealing a complete loss of the pigment network in the former and a faint, preserved reticular pattern in the latter9. RCM offers near-histological resolution imaging of the epidermis and superficial dermis, enabling direct visualization of melanin content and melanocyte morphology10,11.
More recently, artificial intelligence-assisted image analysis and digital imaging technologies have emerged as promising adjuncts for the objective assessment of pediatric pigmentary disorders. Deep-learning models have been developed for pigmentary disorders12: a convolutional neural network achieved diagnostic performance comparable to that of dermatologists in childhood vitiligo, and automated tools have been introduced to detect and quantify the extent of depigmentation, suggesting a future role for standardized, reproducible lesion detection, quantification, and longitudinal monitoring of pediatric hypopigmented disorders13.
DIAGNOSTIC ALGORITHM FOR CHILDHOOD HYPOPIGMENTED DISORDERS
A systematic diagnostic approach begins with identifying whether the lesion represents depigmentation, hypopigmentation, mixed hyper- and hypopigmentation, or pseudo-hypopigmentation arising from non-melanin mechanisms. Wood’s lamp examination is central to this initial classification step. Depigmented lesions, in which melanin is completely absent, emit a bright blue-white (chalky-white) fluorescence owing to accentuated fluorescence of the underlying dermal collagen; hypopigmented lesions, in which melanin is only partially reduced, show a dull, off-white accentuation without such bright fluorescence; and pseudo-hypopigmented lesions, which arise from vascular or optical phenomena rather than a true reduction in melanin, demonstrate no fluorescent accentuation and remain comparable to the surrounding skin. Thus, the pattern of Wood’s lamp fluorescence narrows the differential diagnosis at the outset—bright fluorescence favors vitiligo and other depigmenting disorders, off-white accentuation suggests hypopigmentation, and an absence of accentuation suggests a non-melanotic origin. Subsequently, the onset of lesions provides critical information: congenital lesions presenting at birth or in early infancy suggest developmental defects or genodermatoses, whereas acquired lesions indicate inflammatory, infectious, or autoimmune etiologies. The extent (localized vs. generalized) and natural history (stable vs. evolving) further refine the differential diagnosis (Fig. 2). The following section will focus on a detailed exploration of vitiligo (Fig. 3) and its mimics (Fig. 4), highlighting the key clinical features that distinguish these conditions in children (Table 1).
Fig. 2. Diagnostic algorithm for differential diagnosis of hypopigmented disorders in children.

Fig. 3. Clinical spectrum of vitiligo in children. (A, B) Acrofacial vitiligo with preferential involvement of periorificial and acral sites exposed to repetitive mechanical friction. (C, D) Segmental vitiligo with unilateral distribution along Blaschko’s lines. (E) Undetermined/focal vitiligo, limited depigmentation not yet evolved into nonsegmental or segmental vitiligo. (F) Nonsegmental vitiligo in an infant. (G, H) Mucosal vitiligo involving the lips and genital mucosa. (I) Halo nevi in a patient with vitiligo. Images captured by (A-C, E-H) ultraviolet photography; (D, I) cross-polarization photography.

Fig. 4. Hypopigmented and depigmented disorders mimicking vitiligo in children. (A) Pityriasis alba. (B) Nevus depigmentosus. (C) Hypopigmentation after lichen striatus. (D) Nevus anemicus. (E) Temporal triangular alopecia. (F) Pityriasis versicolor. (G) Dyschromatosis symmetrica hereditaria. (H) Piebaldism. (I) Hypopigmented mycosis fungoides. (J) Pigmentary demarcation lines. (K) Extensive pityriasis alba. (L, M) Hypomelanosis of Ito. Images captured by (A, I-M) ultraviolet photography; (B-H) cross-polarization photography.

Table 1. Key features and diagnostic pearls of childhood hypopigmented disorders.
| Disease | Key features | Diagnostic pearls | |
|---|---|---|---|
| A. Acquired depigmented disorders | |||
| Nonsegmental vitiligo | Chalky-white depigmented macules and patches; bilateral, symmetrical involvement | Blue-white fluorescence under Wood’s lamp | |
| Segmental vitiligo | Chalky-white depigmented macules and patches; unilateral, asymmetric involvement following Blaschko’s lines | Rapid progression followed by early stabilization | |
| Halo nevi | Depigmented rim developing around an existing acquired or congenital melanocytic nevus | Partial or complete regression of central nevus; full-body skin examination for concomitant vitiligo | |
| Chemical leukoderma | Depigmented patches at the site of contact which can spread to remote, unexposed areas | Initial lesion corresponding to the site of exposure | |
| B. Congenital depigmented disorders | |||
| Oculocutaneous albinism | Generalized hypopigmentation or depigmentation of skin, hair, and eyes | Autosomal recessive inheritance; characteristic ocular symptoms | |
| Piebaldism | Well-demarcated depigmented patches on the forehead (white forelock), ventral trunk, and extremities with hyperpigmented islands | Autosomal dominant inheritance; do not expand over time; no hearing or ocular abnormalities | |
| Waardenburg syndrome | Patchy depigmentation similar to piebaldism | Autosomal dominant/recessive inheritance; multisystem involvement (sensorineural deafness, heterochromia irides, and dystopia canthorum) | |
| C. Acquired hypopigmented disorders | |||
| Pityriasis alba | Poorly defined, round-to-ovoid hypopigmented patches with fine scales on face and neck | Dull off-white fluorescence under Wood’s lamp; association with atopic dermatitis or UV exposure | |
| Extensive pityriasis alba | Hypopigmented patches without scales involving the trunk and extremities | Dull off-white fluorescence under Wood’s lamp | |
| Pityriasis versicolor | Multiple, tiny, round hypopigmented macules with fine scales on the seborrheic areas | Yellow-green fluorescence under Wood’s lamp; hyphae and spores on KOH exam; common in infants and adolescents | |
| Lichen striatus | Unilateral, linear hypopigmented macules along Blaschko’s lines; extending on the lower limbs | Preceded by eruption of linear lichenoid papules; common in females | |
| Lichen sclerosus | Well-demarcated, porcelain-white sclerotic patches on anogenital or extragenital regions | Common in premenarchal girls; follicular plugging | |
| Scleroderma | Hypopigmented patches with fibrosis or induration | Retained perifollicular pigmentation (salt-and-pepper appearance) | |
| Pityriasis lichenoides chronica | Recurrent crops of small, red-to-brown maculopapules with scales that resolve into hypopigmented macules | Polymorphous presentation: coexistence of active inflammatory and healed lesions at the same time | |
| Hypopigmented parapsoriasis | Hypopigmented round to oval patches with mild scales on the trunk and proximal limbs (sun-protected sites) | Digitiform extensions; CD8+ predominance | |
| Hypopigmented mycosis fungoides | Hypopigmented patches with fine scales on the trunk and proximal limbs (sun-protected sites) | Atrophy and poikiloderma; epidermotropism of atypical CD8+ T lymphocytes; monoclonal T cell receptor gene rearrangement | |
| Progressive macular hypomelanosis | Symmetric, ill-defined, non-scaly hypopigmented macules or patches on the trunk along the midline | Follicular red/orange fluorescence under Wood's lamp; common in female adolescents | |
| Eruptive hypomelanosis | Sudden onset of symmetric, uniform hypopigmented macules on the forearms and lower limbs | Preceded by prodromal coryzal phase; often involves siblings | |
| Leprosy | Ill-defined hypopigmented or erythematous macules or patches | Sensory loss; prevalent in endemic regions | |
| Kwashiorkor | Patchy, mottled, or diffuse pale areas often with marked desquamation (flaky-paint dermatosis) | Pitting edema and ‘flag sign’ in hair | |
| Postinflammatory hypopigmentation | Ill-defined hypopigmented patch after resolution of prior inflammation, infection, or trauma | Dull off-white fluorescence under Wood’s lamp; corresponding to the site of preceding skin lesion | |
| D. Congenital hypopigmented disorders | |||
| Nevus depigmentosus | Localized, unilateral hypopigmented patch with serrated borders; presents as isolated oval type, segmental block-like type, or streaks | Dull off-white fluorescence under Wood's lamp; no extracutaneous involvement; positive excimer stamp test | |
| Hypomelanosis of Ito | Whorled or linear streaks of hypopigmentation following Blaschko’s lines | Dull off-white fluorescence under Wood's lamp; extracutaneous involvement in 33%–94% | |
| Pigmentary mosaicism | Patterned streaks, whorls, or blocks of hypopigmentation following Blaschko’s lines | Umbrella term that encompasses nevus depigmentosus and hypomelanosis of Ito | |
| Tuberous sclerosis complex | Hypopigmented macules, typically ovoid on one end and pointed on the other, resembling an ash leaf | Present at birth or infancy and remain stable; presence of ≥3 hypomelanotic macules, at least 5 mm in diameter | |
| Metabolic disorders | Generalized pigmentary dilution of skin and hair; often associated with systemic/neurological dysfunction | Diffuse hypopigmentation; presence of other systemic signs (phenylketonuria: musty odor, Menkes: kinky/brittle hair) | |
| E. Mixed hyper- and hypopigmented disorders | |||
| Dyschromatosis symmetrica hereditaria | Mottled hyper- and hypopigmented macules localized to the dorsum of hands/feet and extremities and face | Autosomal dominant inheritance; mixed hyper- and hypopigmentation under Wood’s lamp; facial freckle-like macules | |
| Dyschromatosis universalis hereditaria | Mottled hyper- and hypopigmented macules extending to trunk and extremities | Autosomal dominant inheritance (most common); mixed hyper- and hypopigmentation under Wood's lamp; involvement of mucosa, hair, and nails | |
| F. Pseudo-hypopigmented disorders | |||
| Nevus anemicus | Congenital, well-demarcated hypopigmented patches that appear paler than normal skin | Diascopy makes lesion indistinguishable; no erythema on the lesion upon stroking; remain stable over time | |
| Bier spots | Transient, mottled hypopigmented macules on a cyanotic background involving distal extremities | Disappear when limbs are elevated; common in adolescents | |
| Clear cell papulosis | Tiny, flat-topped, porcelain-white macules and papules along the lower abdomen, pubic area, or milk lines | Early childhood; preponderance in Asian children; large clear cells in the basal layer of eccrine gland origin | |
| Pigmentary demarcation line | Physiologic lines of abrupt transition between areas of normal and hypopigmented skin | Symmetric and occur in characteristic locations according to the subtypes | |
| Temporal triangular alopecia | Congenital, triangular/oval patch of non-scarring alopecia on the frontotemporal region | Normal skin under Wood’s lamp; prominent vellus hairs | |
UV: ultraviolet, KOH: potassium hydroxide.
ACQUIRED DEPIGMENTED DISORDERS
Nonsegmental vitiligo (NSV)
NSV is characterized by well-demarcated, chalky-white depigmented macules and patches that typically exhibit a progressive course involving multiple anatomical sites14. Clinical variants include acrofacial (involving the hands, feet, and periorificial areas), generalized (widespread involvement), mucosal (more than one mucosal site), universal (affecting >80% of body surface area), and mixed type (coexistence with segmental vitiligo [SV])15. Clinical signs such as confetti-like depigmentation, hypochromic lesions, ill-defined borders, inflammatory borders, and Koebner phenomenon are hallmark indicators of active disease progression16.
Patients with NSV exhibit a higher incidence of the Koebner phenomenon, a stronger family history, and more frequent comorbid autoimmune conditions compared to those with SV17,18; collectively, these findings underscore the autoimmune-driven pathogenesis of NSV. Notably, childhood-onset NSV appears to be driven by a more robust genetic predisposition. Genome-wide association studies have identified that MHC class II regulatory variations are significantly associated with early-onset vitiligo (odds ratio, 8.10), suggesting that these variants may accelerate autoreactive T cell activation and precipitate early disease onset19. The most common dermatologic comorbidities in pediatric vitiligo include halo nevus (6.6%), atopic dermatitis (6.1%), and premature graying of hair (5.0%)20. Autoimmune comorbidities include alopecia areata, thyroid disease, rheumatoid arthritis, and pernicious anemia21.
Management of NSV in children includes topical corticosteroids, topical calcineurin inhibitors, and phototherapy22. For younger children who have difficulty entering a whole-body phototherapy unit alone, targeted phototherapy such as the 308-nm excimer laser offers a useful alternative enabling focal delivery of therapeutic UV to lesions. For progressive vitiligo, oral corticosteroid mini-pulse therapy, typically administered as prednisolone on two consecutive days per week, is commonly considered to halt disease progression. Recently, topical ruxolitinib, a Janus kinase inhibitor, has emerged as a promising therapeutic option for NSV, with approval granted for patients aged 12 years and older23.
Segmental vitiligo (SV)
SV is a distinct subtype of vitiligo that presents at a younger age, characterized by unilateral distribution along Blaschko’s lines and early stabilization with limited further spread3,14. SV is more frequent in children than adults, representing up to 36% of childhood vitiligo cases24. The mechanism of SV is thought to involve a localized cytotoxic immune response targeting susceptible melanocytes within a segment harboring somatic mosaicism25. Peripheral immune cell profiles of SV revealed that regulatory T cell or B cell activity was similar to healthy controls, with little or no evidence of increased systemic immunity in SV, which aligns with the lower association of autoimmune comorbidities in SV compared to NSV26.
Although treatment options for SV are largely similar to those for NSV, prominent leukotrichia often occurs early in the disease course of SV, indicating depletion of the melanocyte reservoir and predicting a poorer response to phototherapy. For stable SV lesions unresponsive to phototherapy, surgical interventions, such as suction blister grafting, micro-punch grafting, or cellular grafting, may be considered, but only after at least 12 months of disease stability and the absence of Koebner phenomenon27.
Undetermined or focal vitiligo
Undetermined vitiligo, which is often clinically referred to as focal vitiligo, refers to a presentation that may evolve into SV or NSV15, and accounts for a remarkably large proportion of pediatric vitiligo cases. In a large series of 625 pediatric vitiligo, focal vitiligo was the second most common clinical type (14.4%) after generalized vitiligo28. Similarly in our retrospective study of a pediatric cohort aged ≤12 years (n=627), the frequencies of NSV, SV, and undetermined vitiligo were 31.9%, 49.9%, and 18.2%, respectively (unpublished data). This reflects that pediatric patients tend to seek medical consultation at an earlier stage, before characteristic distribution patterns are fully established. Timely intervention during this window period may partly account for the favorable treatment outcomes of pediatric vitiligo, although long-term studies are needed.
Halo nevus
Halo nevi are acquired melanocytic nevi surrounded by a rim of depigmentation. This phenomenon represents a T cell-mediated immune response against nevus antigens sharing a common pathogenesis with vitiligo, including CD8+ T cell infiltration, elevated interferon-γ expression, and melanocyte destruction29,30. The reported frequency of concomitant vitiligo among individuals with halo nevi ranged from 21% to 48%31, while halo nevus was observed in up to 26% of pediatric vitiligo cohorts32. However, a longitudinal study found that the risk of new-onset vitiligo in children with isolated halo nevi was only 3.7% over 5 years, with early onset, multiplicity, family history of vitiligo, and autoimmune comorbidities identified as risk factors for subsequent vitiligo development31,33.
Chemical leukoderma
Chemical leukoderma is an acquired depigmentation disorder resulting from direct skin exposure to melanocytotoxic chemicals, primarily phenolic compounds. It presents as well-demarcated, often confetti-like, depigmented patches at the site of contact. In children, reported triggers include adhesives, rubber products (e.g., footwear or swimming goggles), cosmetics, toys, and transdermal medications34. The pathogenesis involves direct melanocyte toxicity, which may trigger a secondary T cell-mediated autoimmune response in genetically susceptible individuals, explaining why depigmentation can persist or spread beyond the exposed area, potentially evolving into chemical-induced vitiligo35. It is clinically indistinguishable from vitiligo; a detailed contact history is critical for diagnosis. Management primarily focuses on the identification and avoidance of the causative agent; persistent or spreading cases are treated identically to vitiligo.
CONGENITAL DEPIGMENTED DISORDERS
Oculocutaneous albinism (OCA)
OCA comprises a group of autosomal recessive disorders characterized by disrupted melanin biosynthesis due to mutations in key pigmentation genes (e.g., TYR, OCA2, TYRP1, SLC45A2, SLC24A5, C10orf11/LRMDA), resulting in pigment loss of the hair, skin, and eyes36. Ocular manifestations include nystagmus, reduced visual acuity, photophobia, iris translucency, foveal hypoplasia, and aberrant optic nerve decussation37. Syndromic forms, such as Hermansky-Pudlak syndrome and Chediak-Higashi syndrome, present with additional systemic features, including bleeding diatheses and immunodeficiency, respectively38. Early ophthalmologic evaluation at diagnosis is recommended to monitor visual impairment and associated developmental needs. Genetic counseling should also be offered, ideally in early infancy, to guide clinical management and inform parental decision-making regarding future pregnancies.
Piebaldism
Piebaldism is an autosomal dominant disorder caused by loss-of-function mutations in the KIT gene39. These mutations disrupt the embryological migration, proliferation, and survival of melanoblasts, resulting in depigmented patches of skin and hair that are completely deficient in melanocytes40. The classic presentation includes a well-demarcated, triangular-shaped leukoderma of the central forehead with poliosis (white forelock), and additional depigmented patches on the anterior trunk and extremities with islands of normal skin within the depigmented patches40. Piebaldism rarely has extracutaneous involvement. However, the depigmented areas are at increased risk for sunburn and skin cancer due to absence of melanocytes. Melanocyte transplantation can be considered as a treatment option for piebaldism.
Waardenburg syndrome
Waardenburg syndrome constitutes a group of autosomal dominant genetic disorders caused by mutations in PAX3, MITF, SOX10, EDN3, and EDNRB that are associated with neural crest cell development41. The manifestations of Waardenburg syndrome include congenital sensorineural hearing loss, pigmentary abnormalities of the skin, hair (such as a white forelock or premature graying), and eyes (heterochromia iridum, brilliant blue irides, or hypoplastic irides), as well as distinctive facial features such as dystopia canthorum (lateral displacement of the inner canthi), broad/high nasal root, synophrys (medial eyebrow flare), and underdeveloped alae nasi. Systemic involvement includes musculoskeletal, gastrointestinal, neurological, and craniofacial abnormalities, with the specific manifestations determined by the genetic subtype and underlying mutation42. Early audiologic evaluation is essential to support speech and language development.
ACQUIRED HYPOPIGMENTED DISORDERS
Pityriasis alba (PA)
PA is a common, benign, self-limited skin disorder characterized by ill-defined, round-to-ovoid, slightly scaly hypopigmented patches, frequently seen in children, particularly those with darker skin phototypes43. It predominantly affects the face, especially the cheeks and perioral area in children aged 3 to 16 years. PA is regarded as a minor diagnostic criterion for atopic dermatitis, thought to result from post-inflammatory pigmentary changes44.
Emollients are first-line therapy to address xerosis and restore the skin barrier45. Topical calcineurin inhibitors (e.g., tacrolimus or pimecrolimus) are effective alternatives, especially for facial lesions, and sun protection is recommended to minimize contrast between affected and unaffected skin.
Extensive pityriasis alba (EPA)
EPA is recognized as a rare clinical variant of classic PA, predominantly affecting young children aged 3 to 7 years. It is characterized by a generalized, symmetric distribution of hypopigmented macules and patches involving the trunk, buttocks, and extensor surfaces of the extremities46. Unlike PA, these lesions are typically devoid of a history of atopic dermatitis, lack scaling, and often exhibit a chronic, progressive course, requiring phototherapy. The nosological validity of classifying EPA under the PA spectrum remains debatable, as its clinical profile suggests it may represent a separate entity warranting further characterization.
Pityriasis versicolor
Pityriasis versicolor is a superficial mycosis caused by the Malassezia yeast complex, presenting as hypopigmented or hyperpigmented coalescing macules with fine scale, favoring seborrheic areas such as the upper trunk and neck47. Hypopigmentation results from azelaic acid produced by the organism, which inhibits melanogenesis in part by competitively inhibiting tyrosinase activity48. Wood’s lamp examination may show yellow-green fluorescence49, and a potassium hydroxide test reveals clusters of round yeast cells and short hyphae, described as a “spaghetti and meatballs” pattern. First-line treatment is topical antifungal agents, although pigmentary changes may last months after resolution of active infection50.
Lichen striatus
Lichen striatus is a self-limiting inflammatory dermatosis, predominantly affecting children51. It appears as linear, erythematous, lichenoid papules that follow Blaschko’s lines, typically on the extremities but sometimes on the trunk or face. The lesions typically resolve within 6 to 24 months, with residual hypopigmentation reported in 25% to 59% of cases52. Topical corticosteroids and calcineurin inhibitors have been used for symptomatic management of the inflammatory phase, and the 308-nm excimer laser has demonstrated efficacy for treating hypopigmentation after lichen striatus53.
Lichen sclerosus (LS)
LS is a chronic inflammatory dermatosis that typically affects the anogenital regions predominantly in prepubertal girls, requiring differentiation from genital vitiligo. Extragenital LS presents as ivory-white, atrophic, porcelain-like plaques typically on the upper trunk54. Pathogenesis involves oxidative stress and autoimmunity against extracellular matrix protein 1, disrupting fibroblast and collagen homeostasis55. The standard treatment is ultrapotent topical corticosteroids to prevent scarring or irreversible architectural change56.
Scleroderma
Scleroderma represents a group of autoimmune fibrosing disorders including systemic and localized forms57. In children, localized scleroderma (morphea) is the most common presentation, manifesting as well-demarcated, ivory-colored patches or plaques with induration and skin sclerosis in linear, plaque-like, or en coup de sabre patterns58,59. In systemic sclerosis, hypopigmentation may manifest as “salt-and-pepper” or perifollicular patterns. Decreased CD34-positive dermal dendrocytes in histopathologic examination support the diagnosis of scleroderma60. Early recognition of these pigmentary changes is crucial, as scleroderma can cause disfigurement and functional impairment. Treatment options for localized type include topical corticosteroids, calcineurin inhibitors, phototherapy, and methotrexate61.
Pityriasis lichenoides chronica (PLC)
PLC is a chronic papulosquamous inflammatory skin disorder characterized by pruritic, recurrent, erythematous to brownish papules with mica-like scales that persist for months to years. Lesions are typically distributed on the trunk and extremities and often regress, leaving hypopigmentation62. The etiology is unclear, with proposed associations including infectious triggers, medications, and immunizations62. In children, PLC is more likely to leave dyspigmentation compared with adults, which may persist for years even after resolution of active lesions63. Treatment options include topical corticosteroids, phototherapy, and oral antibiotics62. PLC is generally benign, with low risk of progression to cutaneous T cell lymphoma64.
Hypopigmented parapsoriasis
Hypopigmented parapsoriasis en plaque is a variant of parapsoriasis characterized by hypopigmented, round to oval patches with mild scales on trunk and extremities. The shape and size of the lesions are similar to the classic small plaque parapsoriasis, and the digitiform extension (fingerlike projections) is also an important feature in hypopigmented variant65. Histopathological findings include mild spongiosis, focal exocytosis, and CD8+ T cells predominance over CD4+ T cells66. Although it shows good response to narrowband UVB, long-term follow-up is necessary as 14.7% of patients progressed to hypopigmented mycosis fungoides (HMF) within 2 years65.
Hypopigmented mycosis fungoides (HMF)
HMF is a variant of cutaneous T cell lymphoma that typically presents in younger patients67. The lesions manifest as asymptomatic, persistent, ill-defined, hypopigmented patches, often on sun-protected areas. Histopathologic findings reveal epidermotropism of atypical lymphocytes with cerebriform nuclei, predominantly CD8+ T cells67. HMF is frequently misdiagnosed as vitiligo or EPA in children, leading to significant diagnostic delay. Repeated biopsies from multiple representative lesions over time, combined with T cell receptor gene rearrangement analysis, can substantially increase diagnostic accuracy. The disease generally responds well to skin-directed therapies including topical corticosteroids and phototherapy with favorable long-term prognosis68,69, but approximately 33% of patients with HMF may progress to a higher stage70.
Progressive macular hypomelanosis
Progressive macular hypomelanosis presents as ill-defined, non-scaly hypopigmented macules and patches on the trunk, predominantly affecting adolescents and young adults71. The lesions often coalesce along the midline and rarely extend to the proximal extremities, neck, or head. The pathogenesis is not fully understood, but a potential role of Cutibacterium acnes has been proposed, possibly through porphyrin-mediated inhibition of melanogenesis72. Phototherapy and topical/systemic antibiotics can lead to repigmentation and reduction of lesions, although relapse is not uncommon73.
Eruptive hypomelanosis
Eruptive hypomelanosis is a recently described viral exanthem characterized by sudden onset of asymptomatic, monomorphic, symmetric, discrete hypopigmented macules starting on the forearms and spreading to the lower limbs and face74. It may be preceded by prodromal coryzal symptoms and lymphadenitis, with spontaneous remission in several weeks. The uniform size of lesions, eruptive onset with short natural course, characteristic extensor distribution and frequently noted involvement of siblings suggest a post-viral etiology, analogous to other viral exanthems such as Gianotti-Crosti syndrome.
Leprosy
Leprosy is a chronic infectious disease caused by Mycobacterium leprae that can present as hypopigmented skin lesions with sensory loss75. Although most countries have achieved national elimination, childhood leprosy still persists in endemic areas76. Diagnosis is primarily clinical, supported by histopathology and molecular techniques using polymerase chain reaction, and treatment includes multi-drug therapy77.
Kwashiorkor
Kwashiorkor is a severe form of protein-energy malnutrition that occurs in children with insufficient protein consumption78. Hallmark features include pitting edema, flaky-paint dermatosis (mottled pale skin with desquamation), flag sign in the hair, and diffuse hypopigmentation of skin79. Hypopigmentation results from insufficient essential amino acids, especially tyrosine, and micronutrients such as zinc and essential fatty acids80. Treatment requires careful nutritional rehabilitation.
Postinflammatory hypopigmentation (PIH)
PIH presents as hypopigmented macules or patches at the site of a preceding inflammatory event such as eczema, infection, or trauma, and is more prevalent in darker skin phototypes81. Common iatrogenic causes include topical corticosteroid use or intralesional corticosteroid injection82. Proposed mechanisms include melanocyte destruction or transient inhibition of melanogenesis by inflammatory cytokines such as interleukin (IL)-1, IL-4, IL-6, IL-17, and tumor necrosis factor-α83. PIH is a diagnosis of exclusion, established after identifying and addressing the causative event or any preceding dermatosis. Spontaneous repigmentation is expected but may take months to years.
CONGENITAL HYPOPIGMENTED DISORDERS
Nevus depigmentosus (ND)
ND is one of the most common congenital hypopigmented disorders, representing a nonprogressive form of localized cutaneous mosaicism that typically presents before 3 years of age. Coupe’s diagnostic criteria include: onset at birth or early infancy, stability in size and distribution throughout life, absence of change in texture or sensation, and absence of a hyperpigmented border84. The classic isolated type presents as a well-demarcated, round or oval macule or patch with serrated or saw-toothed borders. Other forms can present as unilateral, band-like or streaked lesions along Blaschko’s lines with demarcation at the ventral midline, though these are often difficult to distinguish from hypomelanosis of Ito85,86. Histopathological findings show a normal number of melanocytes with decreased melanin content due to intrinsic defects in melanosome formation and transport to keratinocytes86. Wood’s lamp examination shows dull off-white accentuation in contrast to chalky-white fluorescence seen in vitiligo. The excimer stamp test can induce pigment in ND but not in vitiligo87. In the excimer stamp test, a depigmented lesion is irradiated with multiple, graded 308-nm excimer laser doses (150, 300, 450, and 600 mJ/cm2), and pigmentation assessed 1 week later distinguishes 2 conditions; ND develops perceptible pigmentation within the irradiated area owing to preserved melanocytes, whereas vitiligo shows no response because of melanocyte loss. Repigmentation has been noted after phototherapy and surgical interventions, although recurrence is common88,89.
Hypomelanosis of Ito
Hypomelanosis of Ito, historically termed incontinentia pigmenti achromians, is a neurocutaneous disorder characterized by streaks, whorls, or patches (marble-cake patterns) of hypopigmentation following Blaschko’s lines90. Extracutaneous anomalies have been reported in 33%–94% of patients; the central nervous system is most frequently involved (developmental delay, intellectual disability, epilepsy including infantile spasms), followed by musculoskeletal, ocular, and craniofacial anomalies, necessitating comprehensive systemic workup91. However, as the phenotype results from a varied array of somatic chromosomal mosaicisms rather than a single genetic cause, reclassification under the broader concept of pigmentary mosaicism has been increasingly favored92,93.
Pigmentary mosaicism
Pigmentary mosaicism is the current preferred umbrella term encompassing historically fragmented diagnoses including segmental ND, hypomelanosis of Ito, and linear and whorled nevoid hypermelanosis. It describes patterned hypo- and/or hyperpigmentation reflecting embryonic migration patterns of genetically distinct skin cell clones, most classically along Blaschko’s lines (streaks, whorls, blocks, V-shapes, S-shapes), but also in phylloid, checkerboard, or patchy patterns94,95,96. The underlying pathogenesis is somatic mosaicism, with recent next-generation sequencing studies identifying post-zygotic mutations in genes such as MTOR and RHOA beyond classically recognized chromosomal abnormalities96. These patterns may represent an isolated cutaneous finding or associated with extracutaneous abnormalities involving the central nervous system, musculoskeletal, and ocular systems97.
Tuberous sclerosis complex (TSC)
TSC is an autosomal dominant, multisystem neurocutaneous disorder caused by pathogenic variants in the TSC1 or TSC2 gene, driving hamartoma formation in multiple organs. Hypopigmented polygonal patches, typically ovoid on one end and pointed on the other (ash-leaf spots) are often the earliest cutaneous manifestation of TSC, detectable at birth or infancy98. Small confetti-like hypopigmented macules may also appear later in childhood or adolescence99. Comprehensive assessment for neurological (epilepsy, cortical tubers, subependymal giant cell astrocytomas), renal, cardiac, ocular, and dental complications is necessary, and mTOR inhibitors (e.g., everolimus) are established for specific organ manifestations100,101.
Metabolic disorders
Several inborn errors of metabolism can lead to disrupted melanin synthesis, primarily by inhibiting tyrosinase pathways. Phenylketonuria102, homocystinuria103, Menkes disease104, histidinemia105, and tyrosinemia type II106 are known to manifest with generalized hypopigmentation due to their respective metabolic interference with melanogenesis.
MIXED HYPER- AND HYPOPIGMENTED DISORDERS
Dyschromatosis symmetrica hereditaria
Dyschromatosis symmetrica hereditaria, also known as reticulate acropigmentation of Dohi, is an autosomal dominant disorder caused by mutations in ADAR1, presenting as mixed hyper- and hypopigmented macules symmetrically distributed on the dorsal hands and feet, with facial freckle-like macules, typically appearing in early childhood107. Neurological complications such as dystonia and brain calcification have been rarely reported.
Dyschromatosis universalis hereditaria
Dyschromatosis universalis hereditaria is a more extensive form characterized by generalized, mottled hyper- and hypopigmented macules affecting the face, trunk, and limbs, with onset usually within the first months of life. Inheritance can be autosomal dominant or recessive, with ABCB6 as the most commonly implicated gene. Rare systemic associations involving hair, nails, mucosa, and neurological or renal abnormalities have been described108,109.
PSEUDO-HYPOPIGMENTED DISORDERS
Nevus anemicus
Nevus anemicus is a congenital vascular anomaly characterized by a focal, bubble-shaped pale patch resulting from persistent vasoconstriction due to hypersensitivity of blood vessels to catecholamines110. Nevus anemicus is diagnosed by the absence of friction-induced erythema, and a positive diascopy test, where the lesion becomes indistinguishable from adjacent skin on pressure. While usually an isolated finding, rare associations with neurofibromatosis type 1, phakomatosis pigmentovascularis, port-wine stains, and TSC111 have been reported.
Bier spots
Bier spots are benign, transient, angiospastic pale macules on the extremities, resulting from localized vasoconstriction rather than pigmentary abnormalities, most common in adolescents and young adults112. Lesions characteristically become prominent with limb dependency and disappear with elevation, reflecting their dynamic, position-dependent nature. The disease is usually benign, but rare association with systemic conditions such as lymphedema, scleroderma renal crisis, and pregnancy-related venous hypertension have been noted113.
Clear cell papulosis
Clear cell papulosis is a rare, benign condition of early childhood characterized by multiple, tiny, flat-topped, porcelain-white macules and papules distributed along the lower abdomen, pubic areas, and milk lines with a predilection for Asian children under 6 years of age114. Histopathological examination of large intraepidermal clear cells along the basal layer, positive for EMA, CEA, CAM 5.2, and GCDFP-15 support an eccrine secretory cell origin. No treatment is required; partial and complete spontaneous resolution were observed in 78.6% and 14.3%, respectively, after 6 to 21 years of follow-up115.
Pigmentary demarcation line
Pigmentary demarcation lines are physiologic, sharply defined transitional boundaries between areas of deeper and lighter pigmentation, most commonly observed in individuals with skin of color116,117,118. These lines are considered normal variants representing atavistic remnants along the Voigt-Futcher’s lines, are typically symmetric and stable, and may become more prominent during pregnancy. Recognition of pigmentary demarcation lines as a benign physiologic finding is important to avoid misdiagnosis as pathologic hypopigmentation.
Temporal triangular alopecia
Temporal triangular alopecia is a benign, non-scarring, triangular or oval patch of hair loss in the frontotemporal region of the scalp, present at birth or early childhood119. The affected area contains normal follicular openings with miniaturized vellus hairs without inflammation or fibrosis120. The replacement of terminal hairs by fine vellus hairs exposes the underlying scalp, creating an optical illusion of a hypopigmented patch that can be mistaken for vitiligo.
CONCLUSION
Hypopigmented disorders are among the most common presentations in pediatric dermatology, and their overlapping clinical features pose considerable diagnostic challenges. The differential is broad, ranging from vitiligo to rare genodermatoses and pseudo-hypopigmentation arising from vascular anomalies. A stepwise diagnostic approach, assessing the degree of pigment loss by Wood's lamp examination, followed by onset, extent, and natural history of the lesions, facilitates accurate differential diagnosis. Notably, focal vitiligo constitutes a substantial proportion of pediatric vitiligo cases, underscoring the importance of accurate diagnosis and early intervention when treatment outcomes are most favorable. Timely and accurate differentiation of vitiligo from its various mimics ultimately facilitates the optimal therapeutic outcomes, prevents unnecessary investigations, and reduces psychological distress for children and their families.
Footnotes
FUNDING SOURCE: This work was supported by Amorepacific research fund, 2024.
CONFLICTS OF INTEREST: The authors have nothing to disclose.
DATA SHARING STATEMENT: None.
References
- 1.Pinto FJ, Bolognia JL. Disorders of hypopigmentation in children. Pediatr Clin North Am. 1991;38:991–1017. doi: 10.1016/s0031-3955(16)38164-0. [DOI] [PubMed] [Google Scholar]
- 2.Ju HJ, Seo JM, Kim SH, Bae JM, Lee YB. Quality of life in parents of children and adolescents with vitiligo: a qualitative study. Ann Dermatol. 2023;35:472–475. doi: 10.5021/ad.22.150. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386:74–84. doi: 10.1016/S0140-6736(14)60763-7. [DOI] [PubMed] [Google Scholar]
- 4.van Geel N, Speeckaert M, Chevolet I, De Schepper S, Lapeere H, Boone B, et al. Hypomelanoses in children. J Cutan Aesthet Surg. 2013;6:65–72. doi: 10.4103/0974-2077.112665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Grinnell M, Hurtado ACM, Guidotti R, Elbuluk N. Digital photography guide for dermatologists with special considerations for diverse populations. JAMA Dermatol. 2025;161:635–641. doi: 10.1001/jamadermatol.2025.0699. [DOI] [PubMed] [Google Scholar]
- 6.Ceresnie MS, Gonzalez S, Hamzavi IH. Diagnosing disorders of hypopigmentation and depigmentation in patients with skin of color. Dermatol Clin. 2023;41:407–416. doi: 10.1016/j.det.2023.02.006. [DOI] [PubMed] [Google Scholar]
- 7.Bae JM, Lee RW. 365-nm narrowband Wood’s lamp for vitiligo and hypopigmentation disorders. J Am Acad Dermatol. 2020;83:e283–e284. doi: 10.1016/j.jaad.2019.08.064. [DOI] [PubMed] [Google Scholar]
- 8.Uitentuis SE, Heilmann MN, Verdaasdonk RM, Bae JM, Luiten RM, Wolkerstorfer A, et al. Ultraviolet photography in vitiligo: image quality, validity and reliability. J Eur Acad Dermatol Venereol. 2020;34:1590–1594. doi: 10.1111/jdv.16226. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Soliman SH, Bosseila M, Hegab DS, Ali DAM, Kabbash IA, AbdRabo FAG. Evaluation of diagnostic accuracy of dermoscopy in some common hypopigmented skin diseases. Arch Dermatol Res. 2024;316:562. doi: 10.1007/s00403-024-03259-8. [DOI] [PubMed] [Google Scholar]
- 10.Lai LG, Xu AE. In vivo reflectance confocal microscopy imaging of vitiligo, nevus depigmentosus and nevus anemicus. Skin Res Technol. 2011;17:404–410. doi: 10.1111/j.1600-0846.2011.00521.x. [DOI] [PubMed] [Google Scholar]
- 11.Liu H, Wang L, Lin Y, Shan X, Gao M. The differential diagnosis of hypopigmented mycosis fungoides and vitiligo with reflectance confocal microscopy: a preliminary study. Front Med (Lausanne) 2021;7:609404. doi: 10.3389/fmed.2020.609404. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Huang H, Wang C, Gao G, Fan Z, Ren L, Wang R, et al. Intelligent diagnosis of hypopigmented dermatoses and intelligent evaluation of vitiligo severity on the basis of deep learning. Dermatol Ther (Heidelb) 2024;14:3307–3320. doi: 10.1007/s13555-024-01296-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Yu S, Chen Z, He J, Wang H. Comparative study of dermatologists and deep learning model on diagnosing childhood vitiligo. Photodiagnosis Photodyn Ther. 2025;54:104727. doi: 10.1016/j.pdpdt.2025.104727. [DOI] [PubMed] [Google Scholar]
- 14.Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med. 2009;360:160–169. doi: 10.1056/NEJMcp0804388. [DOI] [PubMed] [Google Scholar]
- 15.Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2012;25:E1–EE13. doi: 10.1111/j.1755-148X.2012.00997.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Delbaere L, Duponselle J, Herbelet S, Speeckaert R, van Geel N. Predictive value of disease activity signs in vitiligo: an observational study. Exp Dermatol. 2024;33:e15167. doi: 10.1111/exd.15167. [DOI] [PubMed] [Google Scholar]
- 17.Mazereeuw-Hautier J, Bezio S, Mahe E, Bodemer C, Eschard C, Viseux V, et al. Segmental and nonsegmental childhood vitiligo has distinct clinical characteristics: a prospective observational study. J Am Acad Dermatol. 2010;62:945–949. doi: 10.1016/j.jaad.2009.06.081. [DOI] [PubMed] [Google Scholar]
- 18.Martins CPDS, Hertz A, Luzio P, Paludo P, Azulay-Abulafia L. Clinical and epidemiological characteristics of childhood vitiligo: a study of 701 patients from Brazil. Int J Dermatol. 2020;59:236–244. doi: 10.1111/ijd.14645. [DOI] [PubMed] [Google Scholar]
- 19.Jin Y, Roberts GHL, Ferrara TM, Ben S, van Geel N, Wolkerstorfer A, et al. Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression. Nat Commun. 2019;10:391. doi: 10.1038/s41467-019-08337-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Tissera KA, Bitar RA, Hawryluk EB, Garza-Mayers AC. Comorbidities of pediatric vitiligo. JAAD Reviews. 2025;3:131–137. [Google Scholar]
- 21.Lee JH, Ju HJ, Seo JM, Almurayshid A, Kim GM, Ezzedine K, et al. Comorbidities in patients with vitiligo: a systematic review and meta-analysis. J Invest Dermatol. 2023;143:777–789.e6. doi: 10.1016/j.jid.2022.10.021. [DOI] [PubMed] [Google Scholar]
- 22.Renert-Yuval Y, Ezzedine K, Grimes P, Rosmarin D, Eichenfield LF, Castelo-Soccio L, et al. Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients. JAMA Dermatol. 2024;160:453–461. doi: 10.1001/jamadermatol.2024.0021. [DOI] [PubMed] [Google Scholar]
- 23.Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N Engl J Med. 2022;387:1445–1455. doi: 10.1056/NEJMoa2118828. [DOI] [PubMed] [Google Scholar]
- 24.de Barros JC, Machado Filho CD, Abreu LC, de Barros JA, Paschoal FM, Nomura MT, et al. A study of clinical profiles of vitiligo in different ages: an analysis of 669 outpatients. Int J Dermatol. 2014;53:842–848. doi: 10.1111/ijd.12055. [DOI] [PubMed] [Google Scholar]
- 25.Taïeb A, Morice-Picard F, Jouary T, Ezzedine K, Cario-André M, Gauthier Y. Segmental vitiligo as the possible expression of cutaneous somatic mosaicism: implications for common non-segmental vitiligo. Pigment Cell Melanoma Res. 2008;21:646–652. doi: 10.1111/j.1755-148X.2008.00511.x. [DOI] [PubMed] [Google Scholar]
- 26.Willemsen M, Post NF, van Uden NOP, Narayan VS, Chielie S, Kemp EH, et al. Immunophenotypic analysis reveals differences in circulating immune cells in the peripheral blood of patients with segmental and nonsegmental vitiligo. J Invest Dermatol. 2022;142:876–883.e3. doi: 10.1016/j.jid.2021.05.022. [DOI] [PubMed] [Google Scholar]
- 27.Ju HJ, Bae JM, Lee RW, Kim SH, Parsad D, Pourang A, et al. Surgical interventions for patients with vitiligo: a systematic review and meta-analysis. JAMA Dermatol. 2021;157:307–316. doi: 10.1001/jamadermatol.2020.5756. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol. 2003;20:207–210. doi: 10.1046/j.1525-1470.2003.20304.x. [DOI] [PubMed] [Google Scholar]
- 29.Yang Y, Li S, Zhu G, Zhang Q, Wang G, Gao T, et al. A similar local immune and oxidative stress phenotype in vitiligo and halo nevus. J Dermatol Sci. 2017;87:50–59. doi: 10.1016/j.jdermsci.2017.03.008. [DOI] [PubMed] [Google Scholar]
- 30.Musette P, Bachelez H, Flageul B, Delarbre C, Kourilsky P, Dubertret L, et al. Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. J Immunol. 1999;162:1789–1794. [PubMed] [Google Scholar]
- 31.Zhou H, Wu LC, Chen MK, Liao QM, Mao RX, Han JD. Factors associated with development of vitiligo in patients with halo nevus. Chin Med J (Engl) 2017;130:2703–2708. doi: 10.4103/0366-6999.218011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Cohen BE, Mu EW, Orlow SJ. Comparison of childhood vitiligo presenting with or without associated halo nevi. Pediatr Dermatol. 2016;33:44–48. doi: 10.1111/pde.12717. [DOI] [PubMed] [Google Scholar]
- 33.van Geel N, Vandenhaute S, Speeckaert R, Brochez L, Mollet I, De Cooman L, et al. Prognostic value and clinical significance of halo naevi regarding vitiligo. Br J Dermatol. 2011;164:743–749. doi: 10.1111/j.1365-2133.2010.10154.x. [DOI] [PubMed] [Google Scholar]
- 34.Harris JE. Chemical-induced vitiligo. Dermatol Clin. 2017;35:151–161. doi: 10.1016/j.det.2016.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Kuroda Y, Yang L, Katayama I. Pathogenesis of chemical leukoderma and chemical-induced vitiligo. J Dermatol. 2026;53:180–187. doi: 10.1111/1346-8138.70060. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Grønskov K, Ek J, Brondum-Nielsen K. Oculocutaneous albinism. Orphanet J Rare Dis. 2007;2:43. doi: 10.1186/1750-1172-2-43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Kruijt CC, de Wit GC, Bergen AA, Florijn RJ, Schalij-Delfos NE, van Genderen MM. The phenotypic spectrum of albinism. Ophthalmology. 2018;125:1953–1960. doi: 10.1016/j.ophtha.2018.08.003. [DOI] [PubMed] [Google Scholar]
- 38.Okamura K, Suzuki T. Current landscape of oculocutaneous albinism in Japan. Pigment Cell Melanoma Res. 2021;34:190–203. doi: 10.1111/pcmr.12927. [DOI] [PubMed] [Google Scholar]
- 39.Spritz RA, Giebel LB, Holmes SA. Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism. Am J Hum Genet. 1992;50:261–269. [PMC free article] [PubMed] [Google Scholar]
- 40.Oiso N, Fukai K, Kawada A, Suzuki T. Piebaldism. J Dermatol. 2013;40:330–335. doi: 10.1111/j.1346-8138.2012.01583.x. [DOI] [PubMed] [Google Scholar]
- 41.Saleem MD. Biology of human melanocyte development, Piebaldism, and Waardenburg syndrome. Pediatr Dermatol. 2019;36:72–84. doi: 10.1111/pde.13713. [DOI] [PubMed] [Google Scholar]
- 42.Thongpradit S, Jinawath N, Javed A, Jensen LT, Chunsuwan I, Rojnueangnit K, et al. Novel SOX10 mutations in Waardenburg syndrome: functional characterization and genotype-phenotype analysis. Front Genet. 2020;11:589784. doi: 10.3389/fgene.2020.589784. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Miazek N, Michalek I, Pawlowska-Kisiel M, Olszewska M, Rudnicka L. Pityriasis alba--common disease, enigmatic entity: up-to-date review of the literature. Pediatr Dermatol. 2015;32:786–791. doi: 10.1111/pde.12683. [DOI] [PubMed] [Google Scholar]
- 44.Blessmann Weber M, Sponchiado de Avila LG, Albaneze R, Magalhães de Oliveira OL, Sudhaus BD, Cestari TF. Pityriasis alba: a study of pathogenic factors. J Eur Acad Dermatol Venereol. 2002;16:463–468. doi: 10.1046/j.1468-3083.2002.00494.x. [DOI] [PubMed] [Google Scholar]
- 45.Abdel-Wahab HM, Ragaie MH. Pityriasis alba: toward an effective treatment. J Dermatolog Treat. 2022;33:2285–2289. doi: 10.1080/09546634.2021.1959014. [DOI] [PubMed] [Google Scholar]
- 46.Sarifakioglu E. Extensive pityriasis alba in a nonatopic child. Pediatr Dermatol. 2007;24:199–200. doi: 10.1111/j.1525-1470.2007.00379.x. [DOI] [PubMed] [Google Scholar]
- 47.Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002;16:19–33. doi: 10.1046/j.1468-3083.2002.00378.x. [DOI] [PubMed] [Google Scholar]
- 48.Nazzaro-Porro M, Passi S. Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol. 1978;71:205–208. doi: 10.1111/1523-1747.ep12547184. [DOI] [PubMed] [Google Scholar]
- 49.Pietkiewicz P, Konno P, Salwowska N, Mazur E, Cantisani C, Lesiak A. Ultraviolet-induced fluorescence dermatoscopy unmasks dermatoscopically inconspicuous terra firma-forme dermatosis and pityriasis versicolor. Dermatol Pract Concept. 2025;15:5211. doi: 10.5826/dpc.1502a5211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Hu SW, Bigby M. Pityriasis versicolor: a systematic review of interventions. Arch Dermatol. 2010;146:1132–1140. doi: 10.1001/archdermatol.2010.259. [DOI] [PubMed] [Google Scholar]
- 51.Gupta A, Gautam RK, Bhardwaj M. Bilateral lichen striatus: a case report with review of literature. Indian Dermatol Online J. 2017;8:264–266. doi: 10.4103/idoj.IDOJ_304_16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Patrizi A, Neri I, Fiorentini C, Bonci A, Ricci G. Lichen striatus: clinical and laboratory features of 115 children. Pediatr Dermatol. 2004;21:197–204. doi: 10.1111/j.0736-8046.2004.21302.x. [DOI] [PubMed] [Google Scholar]
- 53.Bae JM, Choo JY, Chang HS, Kim H, Lee JH, Kim GM. Effectiveness of the 308-nm excimer laser on hypopigmentation after lichen striatus: a retrospective study of 12 patients. J Am Acad Dermatol. 2016;75:637–639. doi: 10.1016/j.jaad.2016.05.001. [DOI] [PubMed] [Google Scholar]
- 54.Burshtein A, Burshtein J, Rekhtman S. Extragenital lichen sclerosus: a comprehensive review of clinical features and treatment. Arch Dermatol Res. 2023;315:339–346. doi: 10.1007/s00403-022-02397-1. [DOI] [PubMed] [Google Scholar]
- 55.Chan I. The role of extracellular matrix protein 1 in human skin. Clin Exp Dermatol. 2004;29:52–56. doi: 10.1111/j.1365-2230.2004.01440.x. [DOI] [PubMed] [Google Scholar]
- 56.Morrel B, van Eersel R, Burger CW, Bramer WM, Ten Kate-Booij MJ, van der Avoort IAM, et al. The long-term clinical consequences of juvenile vulvar lichen sclerosus: a systematic review. J Am Acad Dermatol. 2020;82:469–477. doi: 10.1016/j.jaad.2019.08.030. [DOI] [PubMed] [Google Scholar]
- 57.Sung JJ, Chen TS, Gilliam AC, McCalmont TH, Gilliam AE. Clinicohistopathological correlations in juvenile localized scleroderma: studies on a subset of children with hypopigmented juvenile localized scleroderma due to loss of epidermal melanocytes. J Am Acad Dermatol. 2011;65:364–373. doi: 10.1016/j.jaad.2010.02.065. [DOI] [PubMed] [Google Scholar]
- 58.Christen-Zaech S, Hakim MD, Afsar FS, Paller AS. Pediatric morphea (localized scleroderma): review of 136 patients. J Am Acad Dermatol. 2008;59:385–396. doi: 10.1016/j.jaad.2008.05.005. [DOI] [PubMed] [Google Scholar]
- 59.Herrick AL, Ennis H, Bhushan M, Silman AJ, Baildam EM. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken) 2010;62:213–218. doi: 10.1002/acr.20070. [DOI] [PubMed] [Google Scholar]
- 60.Thiagarajan A, Yu B, Skupsky H. Histopathologic characteristics of vitiligo-like macules in scleroderma: a case report and review of the literature. Am J Dermatopathol. 2025;47:878–881. doi: 10.1097/DAD.0000000000003097. [DOI] [PubMed] [Google Scholar]
- 61.Zhao M, Wu J, Wu H, Sawalha AH, Lu Q. Clinical treatment options in scleroderma: recommendations and comprehensive review. Clin Rev Allergy Immunol. 2022;62:273–291. doi: 10.1007/s12016-020-08831-4. [DOI] [PubMed] [Google Scholar]
- 62.Geller L, Antonov NK, Lauren CT, Morel KD, Garzon MC. Pityriasis lichenoides in childhood: review of clinical presentation and treatment options. Pediatr Dermatol. 2015;32:579–592. doi: 10.1111/pde.12581. [DOI] [PubMed] [Google Scholar]
- 63.Wahie S, Hiscutt E, Natarajan S, Taylor A. Pityriasis lichenoides: the differences between children and adults. Br J Dermatol. 2007;157:941–945. doi: 10.1111/j.1365-2133.2007.08163.x. [DOI] [PubMed] [Google Scholar]
- 64.Zang JB, Coates SJ, Huang J, Vonderheid EC, Cohen BA. Pityriasis lichenoides: long-term follow-up study. Pediatr Dermatol. 2018;35:213–219. doi: 10.1111/pde.13396. [DOI] [PubMed] [Google Scholar]
- 65.El-Darouti MA, Fawzy MM, Hegazy RA, Abdel Hay RM. Hypopigmented parapsoriasis en plaque, a new, overlooked member of the parapsoriasis family: a report of 34 patients and a 7-year experience. J Am Acad Dermatol. 2012;67:1182–1188. doi: 10.1016/j.jaad.2012.02.030. [DOI] [PubMed] [Google Scholar]
- 66.Benmamán O, Sánchez JL. Comparative clinicopathological study on pityriasis lichenoides chronica and small plaque parapsoriasis. Am J Dermatopathol. 1988;10:189–196. doi: 10.1097/00000372-198806000-00002. [DOI] [PubMed] [Google Scholar]
- 67.Kothari R, Szepietowski JC, Bagot M, Sandhu S, Patil A, Grabbe S, et al. Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management. Int J Dermatol. 2022;61:1458–1466. doi: 10.1111/ijd.16098. [DOI] [PubMed] [Google Scholar]
- 68.Martínez Villarreal A, Gantchev J, Lagacé F, Barolet A, Sasseville D, Ødum N, et al. Hypopigmented mycosis fungoides: loss of pigmentation reflects antitumor immune response in young patients. Cancers (Basel) 2020;12:2007. doi: 10.3390/cancers12082007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139:165–173. doi: 10.1001/archderm.139.2.165. [DOI] [PubMed] [Google Scholar]
- 70.Allen PB, Goyal S, Niyogusaba T, O’Leary C, Ayers A, Tarabadkar ES, et al. Clinical presentation and outcome differences between black patients and patients of other races and ethnicities with mycosis fungoides and Sézary syndrome. JAMA Dermatol. 2022;158:1293–1299. doi: 10.1001/jamadermatol.2022.3601. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Relyveld GN, Menke HE, Westerhof W. Progressive macular hypomelanosis: an overview. Am J Clin Dermatol. 2007;8:13–19. doi: 10.2165/00128071-200708010-00002. [DOI] [PubMed] [Google Scholar]
- 72.Relyveld G, Menke H, Westerhof W. Progressive and extensive hypomelanosis and extensive pityriasis alba: same disease, different names? J Eur Acad Dermatol Venereol. 2006;20:1363–1364. doi: 10.1111/j.1468-3083.2006.01719.x. [DOI] [PubMed] [Google Scholar]
- 73.Thng ST, Long VS, Chuah SY, Tan VW. Efficacy and relapse rates of different treatment modalities for progressive macular hypomelanosis. Indian J Dermatol Venereol Leprol. 2016;82:673–676. doi: 10.4103/0378-6323.182797. [DOI] [PubMed] [Google Scholar]
- 74.Zawar V, Bharatia P, Chuh A. Eruptive hypomelanosis: a novel exanthem associated with viral symptoms in children. JAMA Dermatol. 2014;150:1197–1201. doi: 10.1001/jamadermatol.2014.1499. [DOI] [PubMed] [Google Scholar]
- 75.Peng J, Sun P, Wang L, Wang H, Long S, Yu MW. Leprosy among new child cases in China: epidemiological and clinical analysis from 2011 to 2020. PLoS Negl Trop Dis. 2023;17:e0011092. doi: 10.1371/journal.pntd.0011092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Yang J, Li X, Sun Y, Zhang L, Jin G, Li G, et al. Global epidemiology of leprosy from 2010 to 2020: a systematic review and meta-analysis of the proportion of sex, type, grade 2 deformity and age. Pathog Glob Health. 2022;116:467–476. doi: 10.1080/20477724.2022.2057722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Costa ILV, da Costa PF, da Silva SM, Gobbo AR, Pinto PDDC, Spencer JS, et al. Leprosy among children in an area without primary health care coverage in Caratateua Island, Brazilian Amazon. Front Med (Lausanne) 2023;10:1218388. doi: 10.3389/fmed.2023.1218388. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Liu T, Howard RM, Mancini AJ, Weston WL, Paller AS, Drolet BA, et al. Kwashiorkor in the United States: fad diets, perceived and true milk allergy, and nutritional ignorance. Arch Dermatol. 2001;137:630–636. [PubMed] [Google Scholar]
- 79.Vijayasankar P, Karthikeyan K. Flaky paint dermatosis in kwashiorkor. Am J Trop Med Hyg. 2021;106:3. doi: 10.4269/ajtmh.21-0487. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Heilskov S, Rytter MJ, Vestergaard C, Briend A, Babirekere E, Deleuran MS. Dermatosis in children with oedematous malnutrition (kwashiorkor): a review of the literature. J Eur Acad Dermatol Venereol. 2014;28:995–1001. doi: 10.1111/jdv.12452. [DOI] [PubMed] [Google Scholar]
- 81.Vachiramon V, Thadanipon K. Postinflammatory hypopigmentation. Clin Exp Dermatol. 2011;36:708–714. doi: 10.1111/j.1365-2230.2011.04088.x. [DOI] [PubMed] [Google Scholar]
- 82.Bjorklund KA, Fernandez Faith E. Branching hypopigmentation following intralesional corticosteroid injection: case report and review of the literature. Pediatr Dermatol. 2020;37:235–236. doi: 10.1111/pde.14050. [DOI] [PubMed] [Google Scholar]
- 83.Fu C, Chen J, Lu J, Yi L, Tong X, Kang L, et al. Roles of inflammation factors in melanogenesis (Review) Mol Med Rep. 2020;21:1421–1430. doi: 10.3892/mmr.2020.10950. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Coupe RL. Unilateral systematized achromic naevus. Dermatologica. 1967;134:19–35. doi: 10.1159/000254235. [DOI] [PubMed] [Google Scholar]
- 85.Ullah F, Schwartz RA. Nevus depigmentosus: review of a mark of distinction. Int J Dermatol. 2019;58:1366–1370. doi: 10.1111/ijd.14393. [DOI] [PubMed] [Google Scholar]
- 86.Lee HS, Chun YS, Hann SK. Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients. J Am Acad Dermatol. 1999;40:21–26. doi: 10.1016/s0190-9622(99)70524-4. [DOI] [PubMed] [Google Scholar]
- 87.Bae JM, Eun SH, Kim YH, Park JH, Hann SK. Excimer stamp test distinguishing between nevus depigmentosus and segmental vitiligo. Pigment Cell Melanoma Res. 2019;32:864–865. doi: 10.1111/pcmr.12814. [DOI] [PubMed] [Google Scholar]
- 88.Altalhab S. Modalities of treatment for nevus depigmentosus: review of the literature. J Dermatolog Treat. 2023;34:2258241. doi: 10.1080/09546634.2023.2258241. [DOI] [PubMed] [Google Scholar]
- 89.Bae JM, Jung HM, Chang HS, Kim H, Lee JH, Kim GM. Treatment of nevus depigmentosus using the 308-nm excimer laser: a retrospective study of 14 patients. J Am Acad Dermatol. 2016;75:626–627. doi: 10.1016/j.jaad.2016.04.002. [DOI] [PubMed] [Google Scholar]
- 90.Zakhary G, Ream M. Neurocutaneous disorders identified in the neonatal period and infancy: hypomelanosis of Ito. Semin Pediatr Neurol. 2024;51:101154. doi: 10.1016/j.spen.2024.101154. [DOI] [PubMed] [Google Scholar]
- 91.Pavone P, Praticò AD, Ruggieri M, Falsaperla R. Hypomelanosis of Ito: a round on the frequency and type of epileptic complications. Neurol Sci. 2015;36:1173–1180. doi: 10.1007/s10072-014-2049-1. [DOI] [PubMed] [Google Scholar]
- 92.Ruggieri M, Pavone L. Hypomelanosis of Ito: clinical syndrome or just phenotype? J Child Neurol. 2000;15:635–644. doi: 10.1177/088307380001501001. [DOI] [PubMed] [Google Scholar]
- 93.Taibjee SM, Bennett DC, Moss C. Abnormal pigmentation in hypomelanosis of Ito and pigmentary mosaicism: the role of pigmentary genes. Br J Dermatol. 2004;151:269–282. doi: 10.1111/j.1365-2133.2004.06057.x. [DOI] [PubMed] [Google Scholar]
- 94.Kromann AB, Ousager LB, Ali IKM, Aydemir N, Bygum A. Pigmentary mosaicism: a review of original literature and recommendations for future handling. Orphanet J Rare Dis. 2018;13:39. doi: 10.1186/s13023-018-0778-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 95.Kinsler VA. Mosaic disorders affecting pigmentation - part 1: how to make a clinical diagnosis. Br J Dermatol. 2025;193:819–829. doi: 10.1093/bjd/ljaf262. [DOI] [PubMed] [Google Scholar]
- 96.Saida K, Chong PF, Yamaguchi A, Saito N, Ikehara H, Koshimizu E, et al. Monogenic causes of pigmentary mosaicism. Hum Genet. 2022;141:1771–1784. doi: 10.1007/s00439-022-02437-w. [DOI] [PubMed] [Google Scholar]
- 97.Schaffer JV. Pigmentary mosaicism. Clin Dermatol. 2022;40:322–338. doi: 10.1016/j.clindermatol.2022.02.005. [DOI] [PubMed] [Google Scholar]
- 98.Davis PE, Filip-Dhima R, Sideridis G, Peters JM, Au KS, Northrup H, et al. Presentation and diagnosis of tuberous sclerosis complex in infants. Pediatrics. 2017;140:e20164040. doi: 10.1542/peds.2016-4040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 99.Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657–668. doi: 10.1016/S0140-6736(08)61279-9. [DOI] [PubMed] [Google Scholar]
- 100.DiMario FJ, Jr, Sahin M, Ebrahimi-Fakhari D. Tuberous sclerosis complex. Pediatr Clin North Am. 2015;62:633–648. doi: 10.1016/j.pcl.2015.03.005. [DOI] [PubMed] [Google Scholar]
- 101.Curatolo P, Cusmai R, Cortesi F, Chiron C, Jambaque I, Dulac O. Neuropsychiatric aspects of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:8–16. doi: 10.1111/j.1749-6632.1991.tb37743.x. [DOI] [PubMed] [Google Scholar]
- 102.Elhawary NA, AlJahdali IA, Abumansour IS, Elhawary EN, Gaboon N, Dandini M, et al. Genetic etiology and clinical challenges of phenylketonuria. Hum Genomics. 2022;16:22. doi: 10.1186/s40246-022-00398-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Reish O, Townsend D, Berry SA, Tsai MY, King RA. Tyrosinase inhibition due to interaction of homocyst(e)ine with copper: the mechanism for reversible hypopigmentation in homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1995;57:127–132. [PMC free article] [PubMed] [Google Scholar]
- 104.Dessinioti C, Stratigos AJ, Rigopoulos D, Katsambas AD. A review of genetic disorders of hypopigmentation: lessons learned from the biology of melanocytes. Exp Dermatol. 2009;18:741–749. doi: 10.1111/j.1600-0625.2009.00896.x. [DOI] [PubMed] [Google Scholar]
- 105.Lam WK, Cleary MA, Wraith JE, Walter JH. Histidinaemia: a benign metabolic disorder. Arch Dis Child. 1996;74:343–346. doi: 10.1136/adc.74.4.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Somasundaram A, Chiramel MJ, Sathishkumar D, Korula S. Skin as a window to diagnose inborn errors of metabolism. Indian Journal of Paediatric Dermatology. 2023;24:8–18. [Google Scholar]
- 107.Zhang J, Li M, Yao Z. Updated review of genetic reticulate pigmentary disorders. Br J Dermatol. 2017;177:945–959. doi: 10.1111/bjd.15575. [DOI] [PubMed] [Google Scholar]
- 108.Ahmed F, Do N, Vanderver AL, Treat JR. Dyschromatosis symmetrica hereditaria: a clue to early diagnosis of Aicardi-Goutières syndrome. Pediatr Dermatol. 2024;41:156–157. doi: 10.1111/pde.15437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 109.Murthy AB, Palaniappan V, Karthikeyan K, Anbarasan V. Dyschromatosis universalis hereditaria. Int J Dermatol. 2023;62:1218–1227. doi: 10.1111/ijd.16817. [DOI] [PubMed] [Google Scholar]
- 110.Hernández-Martín A, García-Martínez FJ, Duat A, López-Martín I, Noguera-Morel L, Torrelo A. Nevus anemicus: a distinctive cutaneous finding in neurofibromatosis type 1. Pediatr Dermatol. 2015;32:342–347. doi: 10.1111/pde.12525. [DOI] [PubMed] [Google Scholar]
- 111.Sachs C, Lipsker D. Nevus anemicus and bier spots in tuberous sclerosis complex. JAMA Dermatol. 2016;152:217–218. doi: 10.1001/jamadermatol.2015.3999. [DOI] [PubMed] [Google Scholar]
- 112.Dean SM, Zirwas M. Bier spots are an under-recognized cutaneous manifestation of lower extremity lymphedema: a case series and brief review of the literature. Ann Vasc Surg. 2014;28:1935.e13–1935.e16. doi: 10.1016/j.avsg.2014.07.005. [DOI] [PubMed] [Google Scholar]
- 113.Schoenlaub P, Dupré D, Redon JY, Plantin P. Numerous and large Bier’s spot associated with pregnancy. Eur J Dermatol. 1999;9:230–231. [PubMed] [Google Scholar]
- 114.Wang D, Ho MS, Koh MJ, Giam YC. A case report of clear cell papulosis and a review of the literature. Ann Acad Med Singapore. 2017;46:160–166. [PubMed] [Google Scholar]
- 115.Tseng FW, Kuo TT, Lu PH, Chan HL, Chan MJ, Hui RC. Long-term follow-up study of clear cell papulosis. J Am Acad Dermatol. 2010;63:266–273. doi: 10.1016/j.jaad.2009.08.056. [DOI] [PubMed] [Google Scholar]
- 116.James WD, Carter JM, Rodman OG. Pigmentary demarcation lines: a population survey. J Am Acad Dermatol. 1987;16:584–590. doi: 10.1016/s0190-9622(87)70078-4. [DOI] [PubMed] [Google Scholar]
- 117.Gupta A, Khurana A, Ahuja A, Gautam RK. Description of a new pigmentary demarcation line (type I) Clin Exp Dermatol. 2019;44:e145–e146. doi: 10.1111/ced.13787. [DOI] [PubMed] [Google Scholar]
- 118.Maleville J, Taïeb A. Pigmentary demarcation lines as markers of neural development. Arch Dermatol. 1997;133:1459. doi: 10.1001/archderm.1997.03890470139025. [DOI] [PubMed] [Google Scholar]
- 119.Yamazaki M, Irisawa R, Tsuboi R. Temporal triangular alopecia and a review of 52 past cases. J Dermatol. 2010;37:360–362. doi: 10.1111/j.1346-8138.2010.00817.x. [DOI] [PubMed] [Google Scholar]
- 120.Silva CY, Lenzy YM, Goldberg LJ. Temporal triangular alopecia with decreased follicular density. J Cutan Pathol. 2010;37:597–599. doi: 10.1111/j.1600-0560.2009.01388.x. [DOI] [PubMed] [Google Scholar]
